Allen M Gown

Summary

Publications

  1. ncbi request reprint Controversies and guidelines in tissue-based HER-2/neu testing in breast cancer
    Hadi Yaziji
    MLO Med Lab Obs 34:12-6, 20-1; quiz 22-3. 2002
  2. doi request reprint Current issues in ER and HER2 testing by IHC in breast cancer
    Allen M Gown
    PhenoPath Laboratories, Seattle, WA 98103, USA
    Mod Pathol 21:S8-S15. 2008
  3. doi request reprint High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system
    Allen M Gown
    PhenoPath Laboratories, Seattle, WA 98103, USA
    Mod Pathol 21:1271-7. 2008
  4. ncbi request reprint HER-2 testing in breast cancer using parallel tissue-based methods
    Hadi Yaziji
    PhenoPath Laboratories, Seattle, Wash 98103, USA
    JAMA 291:1972-7. 2004
  5. doi request reprint Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy
    Chun Hing Tse
    PhenoPath Laboratories, 551 N 34th St, Seattle, WA 98103, USA
    J Clin Oncol 29:4168-74. 2011
  6. ncbi request reprint CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas
    Robert W Werling
    PhenoPath Laboratories and IRIS, 551 N 34th Street, Seattle, WA 98103, USA
    Am J Surg Pathol 27:303-10. 2003
  7. ncbi request reprint Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain
    Robert W Werling
    PhenoPath Laboratories, Seattle, Washington, 98103, USA
    Am J Surg Pathol 27:82-90. 2003
  8. ncbi request reprint Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin
    Harry Hwang
    PhenoPath Laboratories, 551 N 34th Street, Seattle, WA 98103, USA
    Appl Immunohistochem Mol Morphol 12:122-6. 2004
  9. ncbi request reprint Immunohistochemical markers of melanocytic tumors
    Hadi Yaziji
    PhenoPath Laboratories, Seattle, Washington 98103, USA
    Int J Surg Pathol 11:11-5. 2003
  10. ncbi request reprint Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome?
    Hadi Yaziji
    PhenoPath Laboratories, 551 North 34th Street, Suite 100, Seattle, WA 98103, USA
    Adv Anat Pathol 9:338-44. 2002

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Controversies and guidelines in tissue-based HER-2/neu testing in breast cancer
    Hadi Yaziji
    MLO Med Lab Obs 34:12-6, 20-1; quiz 22-3. 2002
    ..Tissue-based testing of HER-2/neu in breast cancer represents an example of the latter. This article discusses the available technologies for HER-2/neu testing with some of the sources of testing errors...
  2. doi request reprint Current issues in ER and HER2 testing by IHC in breast cancer
    Allen M Gown
    PhenoPath Laboratories, Seattle, WA 98103, USA
    Mod Pathol 21:S8-S15. 2008
    ....
  3. doi request reprint High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system
    Allen M Gown
    PhenoPath Laboratories, Seattle, WA 98103, USA
    Mod Pathol 21:1271-7. 2008
    ....
  4. ncbi request reprint HER-2 testing in breast cancer using parallel tissue-based methods
    Hadi Yaziji
    PhenoPath Laboratories, Seattle, Wash 98103, USA
    JAMA 291:1972-7. 2004
    ..However, critical examination of FISH on a screening basis has yet to be performed...
  5. doi request reprint Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy
    Chun Hing Tse
    PhenoPath Laboratories, 551 N 34th St, Seattle, WA 98103, USA
    J Clin Oncol 29:4168-74. 2011
    ..However, pangenomic studies have demonstrated that polysomy 17 is rare. This study tests the hypothesis that the use of alternative chromosome 17 reference genes might more accurately assess true HER2 gene status...
  6. ncbi request reprint CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas
    Robert W Werling
    PhenoPath Laboratories and IRIS, 551 N 34th Street, Seattle, WA 98103, USA
    Am J Surg Pathol 27:303-10. 2003
    ..CDX2 expression can be seen, however, in selected non-GI adenocarcinomas such as mucinous ovarian carcinomas and adenocarcinomas of the urinary bladder...
  7. ncbi request reprint Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain
    Robert W Werling
    PhenoPath Laboratories, Seattle, Washington, 98103, USA
    Am J Surg Pathol 27:82-90. 2003
    ..p63 may represent a myoepithelial marker that can complement or replace SMM-HC and/or calponin in the analysis of difficult breast lesions...
  8. ncbi request reprint Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin
    Harry Hwang
    PhenoPath Laboratories, 551 N 34th Street, Seattle, WA 98103, USA
    Appl Immunohistochem Mol Morphol 12:122-6. 2004
    ..These results also contradict recent reports demonstrating WT-1 expression in both breast and lung carcinomas...
  9. ncbi request reprint Immunohistochemical markers of melanocytic tumors
    Hadi Yaziji
    PhenoPath Laboratories, Seattle, Washington 98103, USA
    Int J Surg Pathol 11:11-5. 2003
    ..This article provides a brief overview of these markers in terms of their specificity and sensitivity and offers a discussion of tumors with partial melanocytic differentiation...
  10. ncbi request reprint Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome?
    Hadi Yaziji
    PhenoPath Laboratories, 551 North 34th Street, Suite 100, Seattle, WA 98103, USA
    Adv Anat Pathol 9:338-44. 2002
    ..This commentary discusses the findings of this study, within a broader review of critical issues relating to HER-2/neu testing in breast cancer...
  11. ncbi request reprint Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
    ..Currently, there exist clinical assays that identify ER+/luminal and HER2-overexpressing tumors, and we sought to develop a clinical assay for breast basal-like tumors...
  12. ncbi request reprint Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?
    Hadi Yaziji
    Hum Pathol 35:143-6. 2004
  13. ncbi request reprint Testing for epidermal growth factor receptor in lung cancer: have we learned anything from HER-2 testing?
    Hadi Yaziji
    J Clin Oncol 22:3646; author reply 3646-8. 2004
  14. ncbi request reprint Unmasking the mysteries of antigen or epitope retrieval and formalin fixation
    Allen M Gown
    Am J Clin Pathol 121:172-4. 2004
  15. doi request reprint Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall
    Armita Bahrami
    Texas Children s Hospital and Baylor College of Medicine, Houston, TX, USA
    Mod Pathol 21:795-806. 2008
    ..These findings emphasize the need to employ a panel of markers, to include desmin, myogenin/MyoD1, and genetic study in the diagnosis of primitive round cell neoplasms in all age groups and in all locations...
  16. ncbi request reprint Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases
    Dmitry A Turbin
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada
    Breast Cancer Res Treat 110:417-26. 2008
    ..Our study compares visual scoring of ER in invasive breast cancer by histopathologists to quantitation of staining using a fully automated system...
  17. ncbi request reprint Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encounter
    Russell Vang
    Department of Pathology and Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Am J Surg Pathol 31:854-69. 2007
    ..Those tumors having CK7 expression with or without CK20 expression may be derived from upper gastrointestinal tract-type or sinonasal-type teratomatous elements but could be independent tumors of surface epithelial-stromal origin...
  18. ncbi request reprint p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas
    Russell Vang
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Am J Surg Pathol 31:653-63. 2007
    ....
  19. ncbi request reprint Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance
    Diana N Ionescu
    Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia, Canada
    Am J Surg Pathol 31:26-32. 2007
    ..Disease specific and overall survival is not influenced by NE differentiation and therefore non-small cell lung carcinoma with neuroendocrine differentiation should not be a subclass distinct from the other NSCLC...
  20. ncbi request reprint Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre at Vancouver General Hospital, Prostate Centre, and University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 24:5637-44. 2006
    ....
  21. ncbi request reprint Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7
    Russell Vang
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Mod Pathol 19:1421-8. 2006
    ..Cytokeratin 7 provides the predominant discriminatory value among these markers yet is limited to distinction of primary ovarian tumors from metastases of lower gastrointestinal tract origin...
  22. ncbi request reprint Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Am J Surg Pathol 30:1002-7. 2006
    ....
  23. ncbi request reprint Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity
    Hadi Yaziji
    Ancillary Pathways, Miami, FL 33243 0777, USA
    Mod Pathol 19:514-23. 2006
    ....
  24. ncbi request reprint Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive
    Russell Vang
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Int J Gynecol Pathol 25:83-9. 2006
    ..quot;..
  25. ncbi request reprint Do we need two more mesothelial markers?
    HECTOR A BATTIFORA
    Hum Pathol 36:451-2. 2005
  26. ncbi request reprint Fluorescence in situ hybridization for the detection of t(X;18)(p11.2;q11.2) in a synovial sarcoma tissue microarray using a breakapart-style probe
    Jefferson Terry
    Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Diagn Mol Pathol 14:77-82. 2005
    ..The CISH probes produced signals too weak to interpret. The use of breakapart FISH probes is a relatively quick procedure for detection of synovial sarcoma translocations and can be applied to archival specimens in tissue microarrays...
  27. ncbi request reprint Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases
    Russell Vang
    Department of Pathology, Division of Gynecologic Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Mod Pathol 19:97-105. 2006
    ....